Street research for Supernus Pharmaceuticals, a former Shire sub developing improved drug formulations for epilepsy and ADHD, is expected to be released on 5/27/12. On 4/30/12, the company raised $50.0 million by offering 10,000,000 shares at $5.00. Citi and...read more
Supernus Pharmaceuticals, a former Shire sub developing improved drug formulations for epilepsy and ADHD, raised $50 million on Monday by offering 10 million shares at $5. The company had originally filed to offer 5.8 million shares at a range of $12 to $14...read more
Supernus Pharmaceuticals, a former Shire sub developing improved drug formulations for epilepsy and ADHD, lowered the proposed deal size for its upcoming IPO on Friday. The Rockville, MD-based company now plans to raise $55 million by offering 11 million shares...read more
Street research for Supernus Pharmaceuticals expected on May 27
Street research for Supernus Pharmaceuticals, a former Shire sub developing improved drug formulations for epilepsy and ADHD, is expected to be released on 5/27/12. On 4/30/12, the company raised $50.0 million by offering 10,000,000 shares at $5.00. Citi and...read more
Supernus Pharmaceuticals prices IPO at $5, raising $50 million
Supernus Pharmaceuticals, a former Shire sub developing improved drug formulations for epilepsy and ADHD, raised $50 million on Monday by offering 10 million shares at $5. The company had originally filed to offer 5.8 million shares at a range of $12 to $14...read more
6 US IPOs planned for the week of Apr 30
The following IPOs are expected to price this week:
EverBank Financial Corp (EVER), a financial services company providing banking, lending and investing products to...read more
Supernus Pharmaceuticals decreases proposed IPO deal size; pushes pricing into next week
Supernus Pharmaceuticals, a former Shire sub developing improved drug formulations for epilepsy and ADHD, lowered the proposed deal size for its upcoming IPO on Friday. The Rockville, MD-based company now plans to raise $55 million by offering 11 million shares...read more